Trial Profile
PHASE I / II STUDY OF SEQUENTIAL HIGH-DOSE CHEMOTHERAPY WITH STEM CELL SUPPORT IN CHILDREN YOUNGER THAN 5 YEARS OF AGE WITH HIGH-RISK MEDULLOBLASTOMA
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Cyclophosphamide (Primary) ; Carboplatin; Etoposide; Thiotepa
- Indications Medulloblastoma
- Focus Adverse reactions; Therapeutic Use
- 23 Feb 2021 Planned End Date changed from 1 Sep 2022 to 1 Apr 2021.
- 23 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 18 Sep 2013 New trial record